BACKGROUND: Tetracyclines may be useful in preventing pathological vascular remodeling, thus decreasing the risk of spontaneous hemorrhage from brain vascular malformations. METHODS: Arteriovenous malformation (AVM) and intracranial aneurysm patients undergoing noninvasive management were treated with minocycline or doxycycline (200 mg/day) up to 2 years in a prospective open-label safety pilot trial. The primary outcome was to compare dose-limiting intolerance, defined as treatment-related dose reduction or withdrawal between the agents. RESULTS: Twenty-six patients with AVMs (n = 12) or aneurysms (n = 14) were recruited. Adverse event rates were similar to other reported trials of these agents; 4 of 13 (31%) minocycline and 3 of 13 (23%) doxycycline patients had dose-limiting intolerance (hazard ratio = 3.1, 95% CI = 0.52-18.11, log rank p = 0.70). CONCLUSIONS: It is feasible to propose a long-term trial to assess the potential benefit of tetracycline therapy to decrease hemorrhagic risk in brain vascular malformations. (c) 2008 S. Karger AG, Basel.
BACKGROUND:Tetracyclines may be useful in preventing pathological vascular remodeling, thus decreasing the risk of spontaneous hemorrhage from brain vascular malformations. METHODS: Arteriovenous malformation (AVM) and intracranial aneurysmpatients undergoing noninvasive management were treated with minocycline or doxycycline (200 mg/day) up to 2 years in a prospective open-label safety pilot trial. The primary outcome was to compare dose-limiting intolerance, defined as treatment-related dose reduction or withdrawal between the agents. RESULTS: Twenty-six patients with AVMs (n = 12) or aneurysms (n = 14) were recruited. Adverse event rates were similar to other reported trials of these agents; 4 of 13 (31%) minocycline and 3 of 13 (23%) doxycyclinepatients had dose-limiting intolerance (hazard ratio = 3.1, 95% CI = 0.52-18.11, log rank p = 0.70). CONCLUSIONS: It is feasible to propose a long-term trial to assess the potential benefit of tetracycline therapy to decrease hemorrhagic risk in brain vascular malformations. (c) 2008 S. Karger AG, Basel.
Authors: Benedict Axisa; Ian M Loftus; A Ross Naylor; Steven Goodall; Louise Jones; Peter R F Bell; Matthew M Thompson Journal: Stroke Date: 2002-12 Impact factor: 7.914
Authors: David O Wiebers; J P Whisnant; J Huston; I Meissner; R D Brown; D G Piepgras; G S Forbes; K Thielen; D Nichols; W M O'Fallon; J Peacock; L Jaeger; N F Kassell; G L Kongable-Beckman; J C Torner Journal: Lancet Date: 2003-07-12 Impact factor: 79.321
Authors: Christopher Power; Scot Henry; Marc R Del Bigio; Peter H Larsen; Dale Corbett; Yumi Imai; Voon Wee Yong; James Peeling Journal: Ann Neurol Date: 2003-06 Impact factor: 10.422
Authors: Alexander X Halim; S Claiborne Johnston; Vineeta Singh; Charles E McCulloch; John P Bennett; Achal S Achrol; Stephen Sidney; William L Young Journal: Stroke Date: 2004-05-27 Impact factor: 7.914
Authors: Tomoki Hashimoto; Melissa M Matsumoto; Jenny F Li; Michael T Lawton; William L Young Journal: BMC Neurol Date: 2005-01-24 Impact factor: 2.474
Authors: C A Potter; J Armstrong-Wells; H J Fullerton; W L Young; R T Higashida; C F Dowd; V V Halbach; S W Hetts Journal: J Neurointerv Surg Date: 2009-10-23 Impact factor: 5.836
Authors: Nima Etminan; Bruce A Buchholz; Rita Dreier; Peter Bruckner; James C Torner; Hans-Jakob Steiger; Daniel Hänggi; R Loch Macdonald Journal: Transl Stroke Res Date: 2013-10-30 Impact factor: 6.829